SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz, Juan LU
; Ansari, Daniel
LU
; Sasor, Agata
and Andersson, Roland
LU
(2015)
In Pancreas
44(7).
p.1024-1035
- Abstract
- Pancreatic cancer is a complex and heterogeneous disease that often lacks disease-specific symptoms in early stages. The malignancy is currently the fourth leading cause of cancer-related death in Western countries. In advanced stages, the overall 5-year survival is less than 1% to 2%. Most available treatments lack convincing cost-efficiency determinations and are generally not associated with relevant success rates. Targeting stromal components and stromal depletion is currently becoming an area of extensive research in pancreatic cancer. In this context, a glycoprotein, SPARC (secreted protein acidic and rich in cysteine) appears to play a central role. Still, the role of SPARC in carcinogenesis is controversial because conflicting... (More)
- Pancreatic cancer is a complex and heterogeneous disease that often lacks disease-specific symptoms in early stages. The malignancy is currently the fourth leading cause of cancer-related death in Western countries. In advanced stages, the overall 5-year survival is less than 1% to 2%. Most available treatments lack convincing cost-efficiency determinations and are generally not associated with relevant success rates. Targeting stromal components and stromal depletion is currently becoming an area of extensive research in pancreatic cancer. In this context, a glycoprotein, SPARC (secreted protein acidic and rich in cysteine) appears to play a central role. Still, the role of SPARC in carcinogenesis is controversial because conflicting results have been reported, and the pathways involved in SPARC signaling are not well established. Nonetheless, SPARC is highly expressed in the tumor stroma, principally in peritumoral fibroblasts, and the overexpression of SPARC in this compartment is associated with poorer prognosis. Interestingly, it has been suggested that SPARC present in the tumor stroma could sequester albumin-bound paclitaxel, enhancing the delivery of paclitaxel into the tumor microenvironment. In the present review, we summarize the known associations between SPARC and pancreatic cancer. Moreover, present and future therapies comprising SPARC-targeting are discussed. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8043313
- author
- Vaz, Juan
LU
; Ansari, Daniel
LU
; Sasor, Agata
and Andersson, Roland
LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pancreas
- volume
- 44
- issue
- 7
- pages
- 1024 - 1035
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:26335014
- wos:000361605100004
- scopus:84934336172
- pmid:26335014
- ISSN
- 0885-3177
- DOI
- 10.1097/MPA.0000000000000409
- project
- Pancreatic cancer
- language
- English
- LU publication?
- yes
- id
- 968d9d52-9b8f-4e41-9adf-124a11f5adbf (old id 8043313)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26335014?dopt=Abstract
- date added to LUP
- 2016-04-01 11:05:51
- date last changed
- 2022-03-12 19:47:51
@article{968d9d52-9b8f-4e41-9adf-124a11f5adbf,
abstract = {{Pancreatic cancer is a complex and heterogeneous disease that often lacks disease-specific symptoms in early stages. The malignancy is currently the fourth leading cause of cancer-related death in Western countries. In advanced stages, the overall 5-year survival is less than 1% to 2%. Most available treatments lack convincing cost-efficiency determinations and are generally not associated with relevant success rates. Targeting stromal components and stromal depletion is currently becoming an area of extensive research in pancreatic cancer. In this context, a glycoprotein, SPARC (secreted protein acidic and rich in cysteine) appears to play a central role. Still, the role of SPARC in carcinogenesis is controversial because conflicting results have been reported, and the pathways involved in SPARC signaling are not well established. Nonetheless, SPARC is highly expressed in the tumor stroma, principally in peritumoral fibroblasts, and the overexpression of SPARC in this compartment is associated with poorer prognosis. Interestingly, it has been suggested that SPARC present in the tumor stroma could sequester albumin-bound paclitaxel, enhancing the delivery of paclitaxel into the tumor microenvironment. In the present review, we summarize the known associations between SPARC and pancreatic cancer. Moreover, present and future therapies comprising SPARC-targeting are discussed.}},
author = {{Vaz, Juan and Ansari, Daniel and Sasor, Agata and Andersson, Roland}},
issn = {{0885-3177}},
language = {{eng}},
number = {{7}},
pages = {{1024--1035}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Pancreas}},
title = {{SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.}},
url = {{http://dx.doi.org/10.1097/MPA.0000000000000409}},
doi = {{10.1097/MPA.0000000000000409}},
volume = {{44}},
year = {{2015}},
}